Nantahala Capital Management, LLC

Position in ZVRA — Zevra Therapeutics, Inc.

CIK 1472322 New Canaan, CT

Position in ZVRA

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$23,504,443

+$7,627,897 QoQ

Shares Held

2,521,936

+42.3% QoQ

Ownership

4.27%

of shares outstanding

% of Portfolio

1.42%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2023

11 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Nantahala Capital Management, LLC holds $599,967,806 across 52 Biotechnology names. ZVRA ranks #7 (3.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	SLNO	Soleno Therapeutics Inc	1,744,124	$58,393,271
2	SVRA	Savara Inc	7,344,783	$40,102,515
3	IMUX	Immunic, Inc.	2,506,491	$27,822,050
4	TNGX	Tango Therapeutics, Inc.	1,250,452	$26,159,455
5	LBRX	Lb Pharmaceuticals Inc	1,052,894	$25,964,366
6	MLYS	Mineralys Therapeutics, Inc.	895,481	$24,258,580
7	ZVRA	Zevra Therapeutics, Inc. This page	2,521,936	$23,504,443
8	FULC	Fulcrum Therapeutics, Inc.	3,050,040	$23,393,806

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$23,504,443	2,521,936	+42.3%	Shares	Sole	2026-05-15
2025-12-31	$15,876,546	1,771,936	-10.1%	Shares	Sole	2026-02-13
2025-09-30	$18,753,111	1,971,936	+34.0%	Shares	Sole	2025-11-14
2025-06-30	$12,967,756	1,471,936	0.0%	Shares	Sole	2025-08-14
2025-03-31	$11,024,800	1,471,936	-37.1%	Shares	Sole	2025-05-15
2024-12-31	$19,518,377	2,340,333	-20.0%	Shares	Sole	2025-02-14
2024-09-30	$20,292,705	2,924,021	+20.9%	Shares	Sole	2024-11-14
2024-06-30	$11,855,231	2,419,435	-1.4%	Shares	Sole	2024-08-20
2024-03-31	$14,229,749	2,453,405	0.0%	Shares	Sole	2024-05-15
2023-12-31	$16,069,802	2,453,405	+6.3%	Shares	Sole	2024-02-15
2023-09-30	$11,125,601	2,308,216	—	Shares	Sole	2023-11-14
No filing history on record for this holder in this stock.